Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells

Drug Metabolism and Disposition

Volumn 39, Issue 1, 2011, Pages 77-82

  Paterson, Scott ^a   Sin, Kok L ^a   Tiang, Jacky M ^a   Minchin, Rodney F ^a   Butcher, Neville J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE 1; HISTONE; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; BINDING SITE; CANCER CELL; CELL DENSITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ACETYLATION; ARYLAMINE N-ACETYLTRANSFERASE; CHROMATIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; ISOENZYMES; PROMOTER REGIONS, GENETIC; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 78650748806     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036202     Document Type: Article

References (40)

1. Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, De Belin J, Steers G, Pezzella F, Sachsenmeir KF, et al. (2003) Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 1:826-835.
2. Barker DF, Husain A, Neale JR, Martini BD, Zhang X, Doll MA, States JC, and Hein DW (2006) Functional properties of an alternative, tissue-specific promoter for human arylamine Nacetyltransferase 1. Pharmacogenet Genomics 16:515-525.
3. Boukouvala S and Sim E (2005) Structural analysis of the genes for human arylamine Nacetyltransferases and characterisation of alternative transcripts. Basic Clin Pharmacol Toxicol 96:343-351.
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Butcher NJ, Arulpragasam A, Goh HL, Davey T, and Minchin RF (2005) Genomic organization of human arylamine N-acetyltransferase type I reveals alternative promoters that generate different 5′-UTR splice variants with altered translational activities. Biochem J 387:119-127.
6. Butcher NJ, Boukouvala S, Sim E, and Minchin RF (2002) Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2:30-42.
7. Butcher NJ, Ilett KF, and Minchin RF (2000) Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol 57:468-473.
8. Butcher NJ and Minchin RF (2010) Arylamine N-acetyltransferase 1 gene regulation by androgens requires a conserved heat shock element for heat shock factor-1. Carcinogenesis 31: 820-826.
9. Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM, and Minchin RF (2007) Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res 67:85-92.
10. Butcher NJ, Tiang J, and Minchin RF (2008) Regulation of arylamine N-acetyltransferases. Curr Drug Metab 9:498-504.
11. Cornish VA, Pinter K, Boukouvala S, Johnson N, Labrousse C, Payton M, Priddle H, Smith AJ, and Sim E (2003) Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene. Pharmacogenomics J 3:169-177.
12. Erickson RP, Cao W, Acuña DK, Strnatka DW, Hunter RJ, Chau BT, Wakefield LV, Sim E, and McQueen CA (2008) Confirmation of the role of N-acetyltransferase 2 in teratogen-induced cleft palate using transgenics and knockouts. Mol Reprod Dev 75:1071-1076.
13. Fishel ML, Newell DR, Griffin RJ, Davison R, Wang LZ, Curtin NJ, Zuhowski EG, Kasza K, Egorin MJ, Moschel RC, et al. (2005) Effect of cell cycle inhibition on cisplatin-induced cytotoxicity. J Pharmacol Exp Ther 312:206-213.
14. Gray SG and Ekström TJ (1998) Effects of cell density and trichostatin A on the expression of HDAC1 and p57Kip2 in Hep 3B cells. Biochem Biophys Res Commun 245:423-427.
15. Hatta M and Cirillo LA (2007) Chromatin opening and stable perturbation of core histone:DNA contacts by FoxO1. J Biol Chem 282:35583-35593.
16. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, and Feng Y (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9:29-42.
17. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, and Grant DM (1993) Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14:1633-1638.
18. Hickman D, Pope J, Patil SD, Fakis G, Smelt V, Stanley LA, Payton M, Unadkat JD, and Sim E (1998) Expression of arylamine N-acetyltransferase in human intestine. Gut 42:402-409.
19. Husain A, Zhang X, Doll MA, States JC, Barker DF, and Hein DW (2007) Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements. Drug Metab Dispos 35:1649-1656.
20. Jensen LE, Hoess K, Mitchell LE, and Whitehead AS (2006) Loss of function polymorphisms in NAT1 protect against spina bifida. Hum Genet 120:52-57.
21. Kim SJ, Kang HS, Chang HL, Jung YC, Sim HB, Lee KS, Ro J, and Lee ES (2008) Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer. Oncol Rep 19:663-668.
22. T) method. Methods 25:402-408.
23. Lomberk G and Urrutia R (2005) The family feud: turning off Sp1 by Sp1-like KLF proteins. Biochem J 392:1-11.
24. López-Soto A, Folgueras AR, Seto E, and Gonzalez S (2009) HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 28:2370-2382.
25. Minchin RF (1995) Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem J 307 (Pt 1):1-3.
26. Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, and Butcher NJ (2007) Arylamine N-acetyltransferase I. Int J Biochem Cell Biol 39:1999-2005.
27. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabi B, Ilett KF, and Kadlubar FF (1992) N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun 185:839-844.
28. Ragunathan N, Dairou J, Pluvinage B, Martins M, Petit E, Janel N, Dupret JM, and Rodrigues- Lima F (2008) Identification of the xenobiotic-metabolizing enzyme arylamine Nacetyltransferase 1 as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition. Mol Pharmacol 73:1761-1768.
29. Schroer K, Zhu Y, Saunders MA, Deng WG, Xu XM, Meyer-Kirchrath J, and Wu KK (2002) Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation 105: 2760-2765.
30. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, et al. (2007) Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27:4784-4795.
31. Sim E and Ward A (1995) A possible relationship between N-acetyltransferase and folate metabolism. Hum Exp Toxicol 14:696-697.
32. Singh P, Cho J, Tsai SY, Rivas GE, Larson GP, and Szabo PE 2010) Coordinated allele-specific histone acetylation at the differentially methylated regions of imprinted genes. Nucleic Acids Res doi:10.1093/nar/gkq680.
33. Smith KT and Workman JL (2009) Histone deacetylase inhibitors: anticancer compounds. Int J Biochem Cell Biol 41:21-25.
34. Spange S, Wagner T, Heinzel T, and Krämer OH (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41:185-198.
35. Sugamori KS, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, and Grant DM (2003) Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double- knockout mice. Mol Pharmacol 64:170-179.
36. Tiang JM, Butcher NJ, and Minchin RF (2010) Small molecule inhibition of arylamine Nacetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 393:95-100.
37. Wakefield L, Boukouvala S, and Sim E (2010) Characterisation of CpG methylation in the upstream control region of mouse Nat2: evidence for a gene-environment interaction in a polymorphic gene implicated in folate metabolism. Gene 452:16-21.
38. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, and Mariadason JM (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281:13548-13558.
39. Yokota T, Matsuzaki Y, Miyazawa K, Zindy F, Roussel MF, and Sakai T (2004) Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene 23:5340-5349.
40. Zhao S, Venkatasubbarao K, Li S, and Freeman JW (2003) Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor β type II receptor expression in human pancreatic cancer cells. Cancer Res 63:2624-2630.